Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer

Jie Zang, Qingxing Liu, Huimin Sui, Rongxi Wang, Orit Jacobson, Xinrong Fan, Zhaohui Zhu and Xiaoyuan Chen
Journal of Nuclear Medicine December 2020, 61 (12) 1772-1778; DOI: https://doi.org/10.2967/jnumed.120.242263
Jie Zang
1Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qingxing Liu
1Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huimin Sui
1Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rongxi Wang
1Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orit Jacobson
3Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinrong Fan
4Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhaohui Zhu
1Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoyuan Chen
3Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 61 no. 12 1772-1778
DOI 
https://doi.org/10.2967/jnumed.120.242263
PubMed 
32358086

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication January 14, 2020
  • Accepted for publication April 6, 2020
  • Published online December 1, 2020.

Article Versions

  • previous version (May 1, 2020 - 11:16).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Jie Zang*,1,2,
  2. Qingxing Liu*,1,2,
  3. Huimin Sui1,2,
  4. Rongxi Wang1,2,
  5. Orit Jacobson3,
  6. Xinrong Fan4,
  7. Zhaohui Zhu1,2 and
  8. Xiaoyuan Chen3
  1. 1Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
  2. 2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
  3. 3Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland; and
  4. 4Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
  1. For correspondence or reprints contact: Xinrong Fan, Peking Union Medical College Hospital, 1 Shuaifuyuan, Dongcheng District, Beijing, China. E-mail: pumcfxr{at}126.com
  2. Xiaoyuan Chen, National Institutes of Health, 35A Convent Dr., Room GD937, Bethesda, MD 20892. E-mail: chen9647{at}gmail.com
  3. Zhaohui Zhu, Peking Union Medical College Hospital, 1 Shuaifuyuan, Dongcheng District, Beijing, China. E-mail: 13611093752{at}163.com
  1. ↵* Contributed equally to this work.

View Full Text

Statistics from Altmetric.com

Cited By...

  • 42 Citations
  • 40 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Development of nanotechnology-mediated precision radiotherapy for anti-metastasis and radioprotection
    Yuanbo Pan, Wei Tang, Wenpei Fan, Jianmin Zhang, Xiaoyuan Chen
    Chemical Society Reviews 2022 51 23
  • Advances in aptamer-based nuclear imaging
    Wenyu Song, Yangmeihui Song, Qian Li, Chunhai Fan, Xiaoli Lan, Dawei Jiang
    European Journal of Nuclear Medicine and Molecular Imaging 2022 49 8
  • Advances in PSMA theranostics
    Thomas M. Jeitner, John W. Babich, James M. Kelly
    Translational Oncology 2022 22
  • Developments in 177Lu-based radiopharmaceutical therapy and dosimetry
    Siju C. George, E. James Jebaseelan Samuel
    Frontiers in Chemistry 2023 11
  • Imaging and dosimetric characteristics of 67 Cu
    Michael J Merrick, David A Rotsch, Ashok Tiwari, Jerry Nolen, Thomas Brossard, Jeongseog Song, Thaddeus J Wadas, John J Sunderland, Stephen A Graves
    Physics in Medicine & Biology 2021 66 3
  • Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression
    Xuejun Wen, Pengfei Xu, Xinying Zeng, Jia Liu, Chao Du, Xueyuan Zeng, Xingxing Cheng, Xueqi Wang, Yuanyuan Liang, Tianzhi Zhao, Hongzhang Yang, Huifeng Li, Lingxin Meng, Jianyang Fang, Hongwu Liu, Zijian Zhou, Jingjing Zhang, Xianzhong Zhang, Zhide Guo, Xiaoyuan Chen
    European Journal of Nuclear Medicine and Molecular Imaging 2023 50 9
  • PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging
    John A. Katzenellenbogen
    Cancers 2020 12 8
  • Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review
    Kanchi Patell, Matthew Kurian, Jorge A. Garcia, Prateek Mendiratta, Pedro C. Barata, Angela Y. Jia, Daniel E. Spratt, Jason R. Brown
    Expert Review of Anticancer Therapy 2023 23 7
  • Exploiting Albumin as a Versatile Carrier for Cancer Theranostics
    Yucen Tao, Vivianne Jakobsson, Xiaoyuan Chen, Jingjing Zhang
    Accounts of Chemical Research 2023 56 18
  • A Single-Arm, Low-Dose, Prospective Study of177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    Guochang Wang, Jie Zang, Yuanyuan Jiang, Qingxing Liu, Huimin Sui, Rongxi Wang, Xinrong Fan, Jingjing Zhang, Zhaohui Zhu, Xiaoyuan Chen
    Journal of Nuclear Medicine 2023 64 4

Article usage

Article usage: May 2020 to April 2025

AbstractFullPdf
May 2020699068
Jun 2020123020
Jul 202072011
Aug 2020106014
Sep 20209609
Oct 20208509
Nov 202090042
Dec 2020119235112
Jan 20213272332
Feb 2021254825
Mar 20212522230
Apr 20213032031
May 20211971227
Jun 20215410758
Jul 2021449064
Aug 2021258253
Sep 2021269048
Oct 2021215842
Nov 2021247454
Dec 2021215929
Jan 2022233223
Feb 2022199946
Mar 2022248950
Apr 20222110334
May 20221710658
Jun 2022156632
Jul 2022145222
Aug 2022157862
Sep 2022116438
Oct 2022167932
Nov 20221510041
Dec 2022186326
Jan 2023107227
Feb 20231611243
Mar 20231112842
Apr 2023138642
May 202397328
Jun 202396825
Jul 202384634
Aug 2023125135
Sep 2023137221
Oct 2023914522
Nov 20231026833
Dec 2023267732
Jan 2024157331
Feb 202493718
Mar 202474872
Apr 2024165235
May 2024146139
Jun 202474523
Jul 2024154438
Aug 2024115032
Sep 202476724
Oct 2024138141
Nov 2024164833
Dec 202485010
Jan 2025114223
Feb 20251111940
Mar 2025106533
Apr 20251511464
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (12)
Journal of Nuclear Medicine
Vol. 61, Issue 12
December 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer
Jie Zang, Qingxing Liu, Huimin Sui, Rongxi Wang, Orit Jacobson, Xinrong Fan, Zhaohui Zhu, Xiaoyuan Chen
Journal of Nuclear Medicine Dec 2020, 61 (12) 1772-1778; DOI: 10.2967/jnumed.120.242263

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer
Jie Zang, Qingxing Liu, Huimin Sui, Rongxi Wang, Orit Jacobson, Xinrong Fan, Zhaohui Zhu, Xiaoyuan Chen
Journal of Nuclear Medicine Dec 2020, 61 (12) 1772-1778; DOI: 10.2967/jnumed.120.242263
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Dansylated Amino Acid-Modified Long-Acting PSMA Derivatives 68Ga/177Lu-LNC1011 as Prostate Cancer Theranostics
  • A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
  • Google Scholar

More in this TOC Section

Theranostics

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
Show more Theranostics

Clinical

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
Show more Clinical

Similar Articles

Keywords

  • radioligand therapy
  • 177Lu
  • Evans blue
  • prostate-specific membrane antigen (PSMA)
  • metastatic castration-resistant prostate cancer (mCRPC)
SNMMI

© 2025 SNMMI

Powered by HighWire